Shannon Graham

Executive Vice President, Advocacy and Strategic Alliances, @PhRMA

[Shannon Graham @ShannonC_Graham]

The Washington Post Ed Board is raising concerns about the 340B program, warning it has become a profit center for large hospital systems, driving up costs without clear patient benefit. Greater transparency and accountability are needed. https://t.co/gm4x6SIAE4

[Shannon Graham @ShannonC_Graham]

Diseases like measles and polio once filled hospitals. Today, physicians rarely see them thanks to vaccines. This progress isn’t guaranteed. Continued vaccination and science-based policy are critical to protecting public health and sustaining innovation. https://t.co/AvZe3B0XS3

[Shannon Graham @ShannonC_Graham]

April is National Minority Health Month, a time to raise awareness of disparities in access to care and health outcomes. Advancing equity means addressing social determinants of health and ensuring all communities have access to the care they need. https://t.co/jPgDwmtZws

[Shannon Graham @ShannonC_Graham]

Affordability solutions must address the full drug supply chain. Focusing only on manufacturer prices, like recent proposals in Virginia, misses the real drivers of patient costs, including insurers and PBMs, and risks limiting access and innovation. https://t.co/yN8FNqIpcP

[Shannon Graham @ShannonC_Graham]

16 after the BPCIA, the U.S. has a strong pathway for both biologic innovation and biosimilar competition. The result: more treatment options, over 80 biosimilars approved and billions in savings for patients. Protecting this balance is key. https://t.co/78SskEWWU6

[Shannon Graham @ShannonC_Graham]

Heart disease is already the leading cause of death for women, and new data shows it could rise sharply by 2050 without stronger prevention and early detection. Awareness and action are more important than ever. https://t.co/Rrdp2eOrKK

[Shannon Graham @ShannonC_Graham]

A new hospital drug price finder tool is helping bring transparency to hospital medicine pricing. New analysis shows the same drug can vary dramatically in price. Better transparency helps patients make informed choices. https://t.co/bwJmi9lZiY

[Shannon Graham @ShannonC_Graham]

A new report finds that some urban hospitals are using “dual classification” policies to access rural Medicare benefits, diverting resources meant for rural communities. Rural patients deserve better. #Reform340B https://t.co/XNdZE7MopQ

[Shannon Graham @ShannonC_Graham]

Finding help paying for medicines shouldn’t be complicated. PhRMA’s America’s Medicines is a new resource that helps patients, caregivers, and providers quickly search for available affordability programs and support options all in one place. https://t.co/Km2Q77CyXb

[Shannon Graham @ShannonC_Graham]

Health care costs are rising, but prescription medicines aren’t the primary driver. Nearly 50% of spending on medicines goes to insurers and PBMs. More transparency in the system can help ensure patients see the savings they deserve. https://t.co/yaOX6qcIBZ

[Shannon Graham @ShannonC_Graham]

A bipartisan warning from former lawmakers: cost metrics like QALYs risk devaluing the lives of patients. Congress has long opposed these measures and should act now to ensure access to care isn’t rationed based on perceived “quality of life.” https://t.co/iYBRwpyp0Z

[Shannon Graham @ShannonC_Graham]

PhRMA just announced the 2025 CAREs grant recipients - six community orgs across 15 states helping patients navigate care, understand treatment options, and access medicines. Community-led solutions are essential to improving health equity nationwide. https://t.co/8o07aegm6w

[Shannon Graham @ShannonC_Graham]

Best friends in GA finished cancer treatment and rang the bell together, a moment made possible by medical breakthroughs, compassionate care, and timely access to treatment. These are the outcomes innovation delivers. https://t.co/Fd3L3Wqc6O

[Shannon Graham @ShannonC_Graham]

Cancer survival just hit 70%—a major milestone driven by decades of research and innovation. But the IRA’s “pill penalty” is already slowing small-molecule R&D, with investment down 70%. We must protect the progress patients rely on. https://t.co/nPWCfvfqQ2

[Shannon Graham @ShannonC_Graham]

We’re watching a familiar pattern repeat itself: major hospital systems trying to sidestep accountability for the massive and unnecessary expansion of the 340B program. Unchecked expansion strains patients and taxpayers. #Reform340B
https://t.co/zx35JxdLIV

[Shannon Graham @ShannonC_Graham]

The 340B Rebate Model Pilot affects only 2% of the program's prescriptions.

This pilot program is designed to increase accountability and decrease program abuse without creating hardships for 340B entities.
https://t.co/aEVavab9Kl

[Shannon Graham @ShannonC_Graham]

Investments into research for pill-form medicines have dropped by almost 70% since the introduction of the Inflation Reduction Act.

Learn more ⬇️
https://t.co/z7hHyYIpwS

[Shannon Graham @ShannonC_Graham]

Happy Thanksgiving! This year I'm thankful for the meaningful work I get to be a part of on behalf of patients.

[Shannon Graham @ShannonC_Graham]

It was great to be part of the @_PILMA annual meeting.

The biopharmaceutical industry is investing hundreds of billions of dollars in the U.S., and labor plays a key role. Truly an incredible partnership that boosts American innovation and economic strength.

[Shannon Graham @ShannonC_Graham]

The three largest pharmacy benefit managers drive up the cost of medicine excluded by insurance by 27% every year.

The need for comprehensive PBM reform keeps growing.
https://t.co/2oOtX7DK5r